Promoter Methylation Leads to Hepatocyte Nuclear Factor 4A Loss and Pancreatic Cancer Aggressiveness

By sjmartinez • August 22, 2024

Hatziapostolou M, Koutsioumpa M, Zaitoun AM, Polytarchou C, Edderkaoui M, Mahurkar-Joshi S, Vadakekolathu J, D'Andrea D, Lay AR, Christodoulou N, Pham T, Yau TO, Vorvis C, Chatterji S, Pandol SJ, Poultsides GA, Dawson DW, Lobo DN, Iliopoulos D. Promoter Methylation Leads to Hepatocyte Nuclear Factor 4A Loss and Pancreatic Cancer Aggressiveness. Gastro Hep Adv. 2024 Apr 24;3(5):687-702. doi: 10.1016/j.gastha.2024.04.005. PMID: 39165427; PMCID: PMC11330932.

Tags: Cedars Sinai DoM, Digestive Diseases, DNA methylation, epigenetics, HNF4A, pancreatic cancer, Publications

Hyperaldosteronism Remission after Extended Aldosterone Synthase Inhibition

Brown MJ, Turcu AF, Sam R, Kirschner LS, Hamidi O, Eren A, Ben-Shlomo A, Huang W, Bancos I, Hamrahian AH, Freeman MW. Hyperaldosteronism Remission after[...]

Prevalence and Consequences of Guideline-Directed Indications for Aortic Valve Replacement in the EARLY TAVR Trial

Madhavan MV, Schwartz A, Lindman BR, Pibarot P, Cohen DJ, Oldemeyer JB, Babaliaros V, Fearon WF, Daniels D, Chhatriwalla A, Kavinsky CJ, Shah P, Szerlip[...]

Development of a Quantitative Contrast CT-Based TAVR-Risk Score to Reliably Predict Deformation in Bicuspid Aortic Valves

Suruga K, Patel V, Jilaihawi H, Shitan H, Sheth T, Guo Y, Nagasaka T, Ng D, Chakravarty T, Cheng W, Okada Y, Gupta A, Nakamura[...]